Skip to content
Screener

Halozyme Therapeutics HALO Raw materials

Raw materials at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
$178.8M+2.9%
AptarGroup logo
AptarGroupATR
$151.17M+8.5%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$4.21M+0.9%
TriSalus Life Sciences, Inc. logo
TriSalus Life Sciences, Inc.TLSI
$1.32M-21.2%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$27.85M—
Viatris logo
ViatrisVTRS
$1.46B-5.8%

Other financials

Income statement

See full
Revenue$481.0M+47.7%
Gross profit$401.8M+43.8%
Operating income$287.7M+42.1%
Net income$229.9M+39.2%
EPS (diluted)$1.90+42.9%

Balance sheet

See full
Cash & equivalents$164.0M+165%
Total debt$2.2B+41.6%
Total equity$143.5M-56.9%
Total assets$2.6B+25.5%

Cash flow

See full
Operating cash flow$240.9M+142%
CapEx$4.2M+167%
Free cash flow$236.7M+141%

Valuation

See full
Market cap$12.23B+66.3%
Enterprise value$14.25B+61.3%
P/E17×-4.9×
P/S7.4×+1.1×

Profitability

See full
Gross margin82.4%-1.8pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin48.5%+2.6pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity15.2×+10.6×
Current ratio2.7×-5.7×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:InventoryRawMaterialsNetOfReserves.

The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001159036-26-000104
Line itemJune 30,2026December 31,2025
Raw materials$21,401$21,869
Work-in-process39,39530,920
Finished goods91,178144,454
Total inventories151,974197,243
Less long-term portion (1)(14,839)(20,768)
Total inventories, current$137,135$176,475

Item 1. Financial Statements

FAQ

What is Halozyme Therapeutics's raw materials?
Halozyme Therapeutics (HALO) reported raw materials of $21.4M in Q2 2026.
How has Halozyme Therapeutics's raw materials changed year-over-year?
Halozyme Therapeutics's raw materials increased by 20.3% year-over-year, from $17.79M to $21.4M.
What is the long-term trend for Halozyme Therapeutics's raw materials?
Over 5 years (2020 to 2025), Halozyme Therapeutics's raw materials has grown at a 30.3% compound annual growth rate (CAGR), from $5.81M to $21.87M.
What does raw materials mean?
Unprocessed materials and components purchased for use in manufacturing, valued at cost.

Ask your AI about Halozyme Therapeutics's raw materials.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude